Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

The emergence of novel coronavirus 2019 (COVID-19)1 and the subsequent pandemic present a unique challenge to neurologists managing patients with multiple sclerosis (MS) and related neuroinflammatory disorders, such as neuromyelitis spectrum disorder (NMOSD).

[1]  A. Penman,et al.  Corticosteroids in the Treatment of Acute Optic Neuritis , 2020 .

[2]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[3]  G. Cutter,et al.  Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing , 2019, Neurology.

[4]  W. Brownlee,et al.  Disease-modifying therapies for multiple sclerosis , 2018, British Medical Journal.

[5]  M. Wallin,et al.  Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis , 2018, Multiple sclerosis.

[6]  Yinshan Zhao,et al.  Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[7]  M. Greenwood,et al.  Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments , 2017, Front. Neurol..

[8]  Yinshan Zhao,et al.  Infection-related health care utilization among people with and without multiple sclerosis , 2017, Multiple sclerosis.

[9]  H. Hartung,et al.  Disease-modifying therapies and infectious risks in multiple sclerosis , 2016, Nature Reviews Neurology.

[10]  G. Edan,et al.  Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP) , 2016 .

[11]  W. Freeman.  Intensive care unit admission in multiple sclerosis: Increased incidence and increased mortality , 2014, Neurology.

[12]  H. Fukaura.  [Disease modifying therapies in multiple sclerosis]. , 2014, Nihon rinsho. Japanese journal of clinical medicine.

[13]  Nancy Xiaonan Yu,et al.  Dramatically changing rates and reasons for hospitalization in multiple sclerosis , 2014, Neurology.

[14]  R. Marrie,et al.  Intensive care unit admission in multiple sclerosis , 2014, Neurology.

[15]  Neil R. Miller,et al.  A Randomized, Controlled Trial of Corticosteroids in the Treatment of Acute Optic Neuritis , 1992 .